| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $11.6M | 0.02% | 96.60K | +88% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BLLN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 4, 2026 | Ten Bosch John Roderick Ph.D.Officer | Sale at price 105.15 per share. | 2.8K | $298.00K |
| Oct 4, 2026 | Tsao David Ph.D.Chief Technology Officer | Sale at price 105.56 - 110.09 per share. | 20K | $2.16M |
| Oct 4, 2026 | Tsao David Ph.D.Chief Technology Officer | Conversion of Exercise of derivative security at price 2.80 per share. | 20K | $56.00K |
| Sep 27, 2026 | Atay Oguzhan Ph.D.Chief Executive Officer | Sale at price 120.64 per share. | 11K | $1.33M |
| Sep 27, 2026 | Atay Oguzhan Ph.D.Chief Executive Officer | Conversion of Exercise of derivative security at price 2.80 per share. | 8.3K | $23.33K |
| Sep 23, 2026 | Ten Bosch John Roderick Ph.D.Officer | Sale at price 120.00 per share. | 1.4K | $169.92K |
| Sep 23, 2026 | Tsao David Ph.D.Chief Technology Officer | Sale at price 125.00 per share. | 3.3K | $416.63K |
| Sep 23, 2026 | Tsao David Ph.D.Chief Technology Officer | Conversion of Exercise of derivative security at price 2.80 per share. | 3.3K | $9.33K |
| Sep 20, 2026 | Ten Bosch John Roderick Ph.D.Officer | Sale at price 106.61 per share. | 1.4K | $150.96K |
| Sep 16, 2026 | Lynch Thomas PGeneral Counsel | Sale at price 110.29 - 110.36 per share. | 35.1K | $3.87M |
| Sep 16, 2026 | Lynch Thomas PGeneral Counsel | Conversion of Exercise of derivative security at price 8.65 - 30.78 per share. | 35.1K | $477.90K |
| Sep 13, 2026 | Atay Oguzhan Ph.D.Chief Executive Officer | Sale at price 98.00 - 101.49 per share. | 30.3K | $3.03M |
| Sep 13, 2026 | Atay Oguzhan Ph.D.Chief Executive Officer | Conversion of Exercise of derivative security at price 2.80 per share. | 25K | $70.00K |
| Sep 9, 2026 | Sakakibara Shan RikuOfficer | Stock Gift at price 0.00 per share. | 3.5K | — |
| Sep 8, 2026 | Atay Oguzhan Ph.D.Chief Executive Officer | Stock Gift at price 0.00 per share. | 20K | — |
| Sep 8, 2026 | Ten Bosch John Roderick Ph.D.Officer | Sale at price 97.54 per share. | 1.4K | $138.12K |
| Sep 8, 2026 | Tsao David Ph.D.Chief Technology Officer | Sale at price 97.54 - 100.00 per share. | 20K | $1.98M |
| Sep 8, 2026 | Tsao David Ph.D.Chief Technology Officer | Conversion of Exercise of derivative security at price 2.80 per share. | 20K | $56.00K |
| Sep 7, 2026 | Tsao David Ph.D.Chief Technology Officer | Stock Gift at price 0.00 per share. | 20K | — |
| Sep 7, 2026 | Lynch Thomas PGeneral Counsel | Sale at price 96.47 - 101.41 per share. | 20K | $2.00M |
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
Buy / hold / sell counts